Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24 sept. 2024 11h09 HE
|
Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Impulse Dynamics Expands Executive Leadership Team
24 sept. 2024 09h00 HE
|
Impulse Dynamics
Marlton, NJ, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership...
Tersa Earth and Silica-X Sign MoU to Revolutionize Mining and Waste Management with AI-Powered Biotech and Zero-Waste Solutions
24 sept. 2024 09h00 HE
|
Tersa Earth Innovations Inc
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fresh off its recognition as a Top Innovator in the World Economic Forum’s (WEF) Sustainable Mining Challenge, Tersa Earth Innovations Inc. announces...
YPrime Recognized as Trailblazer in Patient Engagement by Everest Group
24 sept. 2024 08h42 HE
|
Y-Prime, LLC
YPrime has been recognized as a Trailblazer in patient engagement by Everest Group for its innovative solutions that enhance clinical trial participation.
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)
24 sept. 2024 08h00 HE
|
Araris Biotech
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
24 sept. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
24 sept. 2024 01h00 HE
|
Biogen Inc.
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
Digital Utilities Ventures Reports Strong Fiscal Year 2024 - Advancing Leadership in Green Technologies
23 sept. 2024 09h00 HE
|
Digital Utilities Ventures, Inc.
Digital Utilities Ventures Reports Strong Fiscal Year 2024 - Advancing Leadership in Green Technologies
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
23 sept. 2024 08h00 HE
|
European Microbiome Innovation for Health
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET - The European Microbiome...